Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: A new source for graft facilitating cells in bone marrow transplantation

Human Immunology

Volumn 66, Issue 6, 2005, Pages 644-652

  Aviner, Shraga ^a   Yao, Xin ^b   Krauthgamer, Rita ^a   Gan, Yehudit ^a   Goren Arbel, Rinat ^a   Klein, Tirza ^c   Tabilio, Antonio ^d   McMannis, John D ^b   Champlin, Richard ^b   Martelli, Massimo F ^d   Bachar Lustig, Esther ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RABIN MEDICAL CENTER   (Israel)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cytotoxic lymphocytes; GvHD

Indexed keywords

CHROMIUM 51; INTERLEUKIN 2;

ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; CELL DEATH; CELL SURVIVAL; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LARGE SCALE PRODUCTION; LYMPHOCYTE CLONE; LYMPHOCYTE CULTURE; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL;

ANIMALS; BONE MARROW TRANSPLANTATION; CLONE CELLS; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS;

EID: 21544444739     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2005.03.004     Document Type: Article

References (45)

1. M.F. Martelli, F. Aversa, E. Bachar-Lustig, A. Velardi, S. Reich-Zelicher, A. Tabilio, H. Gur, Y. Reisner Transplants across human leukocyte antigen barriers Semin Hematol 39 2002 48
2. H. Einsele, H. Hebart Cellular immunity to viral and fungal antigens after stem cell transplantation Curr Opin Hematol 9 2002 485
3. K.V. Komanduri Thymic function and allogeneic T-cell responses in stem-cell transplantation Cytotherapy 4 2002 333
4. W.J. Hogan, R. Storb Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease Immunol Res 28 2003 1
5. S. Giralt Update on non-myeloablative stem cell transplantation for hematologic malignancies Int J Hematol 76 2002 368
6. S. Slavin Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts Transplant Proc 34 2002 3371
7. D.G. Maloney, B.M. Sandmaier, S. Mackinnon, J.A. Shizuru Non-myeloablative transplantation Hematology (Am Soc Hematol Educ Program) 1 2002 392
8. R.G. Miller An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it Nature 287 1980 544
9. R.G. Miller Lymphoid suppressor cells E.E. Sercarz A.J. Cunningham Strategies of Immune Regulation 1980 Academic Press New York
10. R.G. Miller, H. Derry A cell population in nu/nu spleen can prevent generation of cytotoxic lymphocytes by normal spleen cells against self antigens of the nu/nu spleen J Immunol 122 1979 1502
11. S. Muraoka, R.G. Miller Cells in bone marrow and in T cell colonies grown from bone marrow can suppress generation of cytotoxic T lymphocytes directed against their self antigens J Exp Med 152 1980 54
12. P.J. Fink, R.P. Shimonkevitz, M.J. Bevan Veto cells Annu Rev Immunol 6 1988 115
13. M.H. Claesson, C. Ropke Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures Curr Top Microbiol Immunol 126 1986 213
14. M.H. Claesson, R.G. Miller Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. I. CTL clones express strong anti-self suppressive activity J Exp Med 160 1984 1702
15. D.J. Cassell, J. Forman Regulation of the cytotoxic T lymphocyte response against Qa-1 alloantigens J Immunol 144 1990 4075
16. + antigen-specific T cells after in vivo exposure to male antigen J Immunol 148 1992 3740
17. T. Tscherning, M.H. Claesson Veto suppression the peripheral way of T cell tolerization Exp Clin Immunogenet 10 1993 179
18. S.R. Sambhara, R.G. Miller Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC Science 252 1991 1424
19. + cells whose class I MHC can bind the peptide J Immunol 152 1994 1103
20. M.H. Claesson Veto cell H-2 antigens veto cell activity is restricted by determinants encoded by K, D, and I MHC regions Cell Immunol 109 1987 360
21. K. Hiruma, H. Nakamura, P.A. Henkart, R.E. Gress Clonal deletion of postthymic T cells veto cells kill precursor cytotoxic T lymphocytes J Exp Med 175 1992 863
22. E. Bachar-Lustig, S. Reich-Zeliger, Y. Reisner Anti-third-party veto CTLs overcome rejection of hematopoietic allografts synergism with rapamycin and BM cell dose Blood 102 2003 1943
23. J.E. Ryser, H.R. MacDonald Limiting dilution analysis of alloantigen-reactive T lymphocytes. I. Comparison of precursor frequencies for proliferative and cytolytic responses J Immunol 122 1979 1691
24. + regulatory T cells implications for transplantation tolerance Transplant Immunol 11 2003 277
25. E. Bachar-Lustig, H.W. Li, H. Marcus, Y. Reisner Tolerance induction by megadose stem cell transplants synergism between SCA-1+ Lin- cells and nonalloreactive T cells Transplant Proc 30 1998 4007
26. M.R. Silva, A. Parreira, J.L. Ascensao Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts conditions for in vitro expansion Exp Hematol 23 1995 1676
27. + cytotoxic cells from human umbilical cord blood Exp Hematol 29 2001 104
28. Y.K. Tam, J.A. Martinson, K. Doligosa, H.G. Klingemann Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy Cytotherapy 5 2003 259
29. H.J. Wajchman, C.W. Pierce, V.A. Varma, M.M. Issa, J. Petros, K.E. Dombrowski Ex vivo expansion of CD8(+)CD56(+) and CD8(+)CD56(-)natural killer T cells specific for MUC1 mucin Cancer Res 64 2004 1171
30. + T cells of Tc2 phenotype potently inhibit marrow graft rejection Blood 91 1998 4045
31. + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease J Immunol 157 1996 4811
32. B.R. Blazar, P.A. Taylor, A. Panoskaltsis-Mortari, D.A. Vallera Rapamycin inhibits the generation of graft versus host disease and graft versus leukemia causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines J Immunol 160 1998 5355
33. P. Taylor, C. Lees, J. Wilson, M. Ehrhardt, M. Campbell, R. Noelle, B. Blazar Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions Blood 100 2002 3400
34. M. Guillet, F. Sebille, J.P. Soulillou TCR usage in naive and committed alloreactive cells implications for the understanding of TCR biases in transplantation Curr Opin Immunol 13 2001 566
35. W.A. Marijt, M.H. Heemskerk, F.M. Kloosterboer, E. Goulmy, M.G. Kester, M.A. Van Der Hoorn, S.A. Van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J.W. Drijfhout, J.J. Van Rood, R. Willemze, J.H. Falkenburg Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2 specific T cells can induce complete remissions of relapsed leukemia Proc Natl Acad Sci U S A 100 2003 2742
36. T. Mutis, E. Blokland, M. Kester, E. Schrama, E. Goulmy Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation Blood 100 2002 547
37. T. Mutis, E. Goulmy Targeting alloreactive T cells to hematopoietic system specific minor histocompatibility antigens for cellular immunotherapy of hematological malignancies after stem cell transplantation Ann Hematol 81 Suppl 2 2002 38
38. J.J. Molldrem, S. Kant, W. Jiang, S. Lu The basis of T-cell mediated immunity to chronic myelogenous leukemia Oncogene 21 2002 8668
39. S.K. Nair, A. Heiser, D. Boczkowski, A. Majumdar, M. Naoe, J. Lebkowski, J. Vieweg, E. Gilboa Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells Nat Med 6 2000 1011
40. F.A. Arditi, S. Aviner, B. Dekel, R. Krauthgamer, J. Gan, A. Nagler, A. Tabilio, M. Martelli, A. Berrebi, Y. Reisner Eradication of B-CLL by autologous and allogeneic host non-reactive anti-third-party CTLs Blood 105 2005 3365
41. M. Sykes, M.L. Romick, D.H. Sachs Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells Proc Natl Acad Sci U S A 87 1990 5633
42. Y.G. Yang, J.J. Sergio, D.A. Pearson, G.L. Szot, A. Shimizu, M. Sykes Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice Blood 90 1997 4651
43. G.R. Hill, K.R. Cooke, T. Teshima, J.M. Crawford, J.C. Keith, Y.S. Brinson, D. Bungard, J.L. Ferrara Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation J Clin Invest 102 1998 115
44. Y. Young-Guang, J. Ki, M. Sykes INFgamma downmodulates graft-versus-host disease while mediating graft-versus-leukemic effect Blood 94 Suppl Pt 1 1999 365a
45. V. Buoussiontis, W. Murphy, J. Zeller, A. Berezovskaya, M. Roncarolo, Z. Chen, L. Nadler, B. Balzer Molecular basis of GVHD control induced by IL-10 and TGF-beta Blood 94 Suppl Pt 1 1999 604a